Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 61% of modeled bridge. Strengths: Net-to-Gross Ratio. Risks: Occupancy Rate, Revenue per Bed. Risk-adjusted uplift: $2.1M (vs $3.4M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $1.3M | $1.3M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $1.3M | $36K | $1.3M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $200K | $593K | $793K | $2.5M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $42K | $42K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 37.9% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $326K | $651K | $977K | $1.3M | $1.3M | $1.3M | $1.3M |
| Denial Rate Reduction | $0 | $322K | $645K | $967K | $1.3M | $1.3M | $1.3M | $1.3M |
| A/R Days Reduction | $0 | $264K | $528K | $793K | $793K | $793K | $793K | $793K |
| Clean Claim Rate | $0 | $21K | $42K | $42K | $42K | $42K | $42K | $42K |
| Cumulative | $0 | $933K | $1.9M | $2.8M | $3.4M | $3.4M | $3.4M | $3.4M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $3.4M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 57% / 9.6x | 61% / 11.0x | 65% / 12.4x | 67% / 13.1x | 69% / 13.8x |
| 9.0x | 52% / 8.1x | 57% / 9.4x | 61% / 10.7x | 62% / 11.3x | 64% / 11.9x |
| 10.0x | 48% / 7.0x | 52% / 8.1x | 56% / 9.3x | 58% / 9.8x | 60% / 10.4x |
| 11.0x | 43% / 6.1x | 48% / 7.1x | 52% / 8.1x | 54% / 8.7x | 56% / 9.2x |
| 12.0x | 40% / 5.3x | 44% / 6.2x | 48% / 7.2x | 50% / 7.7x | 52% / 8.1x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 18% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 5.3x, adding 3.1 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $5.8M | — | $5.8M | 8.9% |
| Year 1 | $6.0M | +$2.3M | $8.3M | 12.7% |
| Year 2 | $6.2M | +$3.4M | $9.6M | 14.7% |
| Year 3 | $6.3M | +$3.4M | $9.8M | 15.0% |
| Year 4 | $6.5M | +$3.4M | $10.0M | 15.3% |
| Year 5 | $6.7M | +$3.4M | $10.1M | 15.6% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $651K | $977K | $1.3M | $1.6M |
| Denial Rate Reductio | $645K | $967K | $1.3M | $1.5M |
| A/R Days Reduction | $396K | $594K | $793K | $951K |
| Clean Claim Rate | $21K | $31K | $42K | $50K |
| Total | $1.7M | $2.6M | $3.4M | $4.1M |
Peer Context — Where This Hospital Sits
Key metrics vs 22 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 8.9% | -6.0% | 5.9% | 13.3% | P65 |
| Net-to-Gross | 12.6% | 18.1% | 26.5% | 37.8% | P0 |
| Occupancy | 23.1% | 27.4% | 48.1% | 68.8% | P9 |
| Rev/Bed | $708K | $431K | $952K | $1.2M | P30 |
| Exp/Bed | $645K | $494K | $1.1M | $1.6M | P32 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.